Roche's phase III MUSETTE trial of Ocrevus high dose in people with relapsing multiple sclerosis fails to meet primary ...
Roche announced that the phase III MUSETTE trial comparing a high dose of Ocrevus (ocrelizumab) intravenous (IV) infusion to the currently approved Ocrevus IV 600 mg dose in people with relapsing multiple sclerosis (RMS) did not meet its primary endpoint …